Accessibility Menu
Bausch Health Companies logo

Bausch Health Companies(TSX) BHC

Market CapCA$3.30BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1994)+2,003%
5 Year-74%
1 Year-11%
1 Month+32%
CA$8.95
+1.36%
+0.12Today
Bausch Health Companies last closing stock price
MetricPriceDate
Last closeCAD 8.832026-08-13
Bausch Health Companies stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+6.64%CAD 8.282026-08-06
1 month+31.99%CAD 6.692026-07-14
3 month+18.21%CAD 7.472026-05-15
Year to date-7.35%CAD 9.532025-12-31
1 year-10.54%CAD 9.872025-08-13
3 year-22.41%CAD 11.382023-08-14
5 year-74.37%CAD 34.452021-08-13
Since inception+2,002.5%CAD 0.421994-04-05

Bausch Health Companies Financials at a Glance

Market Cap

CA$3.30BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$9.01B

Net Income (TTM)

-$1.08B

EPS (TTM)

-CA$4.06

P/E Ratio

-2.18

Dividend

CA$0.00

Beta (Volatility)

1.25 (Average)

Price

CA$8.95

Volume

382,249

Open

CA$8.70

Previous Close

CA$8.83

Daily Range

CA$8.57 - CA$9.05

52-Week Range

CA$6.10 - CA$11.97

Estimated Earnings Date

Oct 28, 2026

BHC News

Contrary

Why Bausch Health Companies Stock Has Gained Nearly 12% Halfway Through 2018

George Budwell, PhDJul 19, 2018

Valeant Settles With Anacor for $142.5 Million

Justin LoiseauOct 28, 2013

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Bausch Health Companies

Bausch Health Companies Inc. is a global healthcare enterprise focused on the creation, production, and sale of a diverse range of pharmaceutical, medical device, and over-the-counter products. The company primarily targets therapeutic areas such as eye health, digestive system issues, and dermatological conditions.

Products and Services
  • Bausch + Lomb: Vision care and surgical solutions
  • Salix: Gastroenterology products in the U.S.
  • Ortho Dermatologics: Dermatological products and medical aesthetic devices
Growth Outlook
  • Recent quarterly revenue reached $2.48 billion, indicating strong market demand
  • Operating income margin improved to 20.6% in Q1 2026
  • Focus on expanding international markets to drive future growth
Financial Highlights
  • Trailing twelve months revenue of $9.8 billion, showcasing consistent performance
  • Net income for Q1 2026 was -$1.4 billion, reflecting ongoing restructuring efforts
  • Cash flow from operations was $230 million in Q1 2026, indicating operational efficiency
Bausch Health Companies Inc. operates through five key divisions, each specializing in different therapeutic areas. The company has shown resilience in its financial performance, with a notable revenue figure for the trailing twelve months. Despite facing challenges reflected in net income, the operating income margin has shown improvement, suggesting effective cost management strategies. The focus on expanding into international markets and enhancing product offerings positions the company for potential growth in the healthcare sector. Investors may find Bausch Health's diverse portfolio and strategic initiatives appealing as the company navigates its path forward.
AI Generated • Jul 23, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

20,300

CEO

Thomas J. Appio

Website

www.bauschhealth.com

Headquarters

Laval, QC H7L 4A8, CA

BHC Financials

Key Financial Metrics (TTM)

Gross Margin

71.82%

Operating Margin

25.44%

Net Income Margin

-10.12%

Return on Equity

88.77%

Return on Capital

10.76%

Return on Assets

-4.43%

Earnings Yield

-45.87%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

CA$3.30BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

373.99M

Volume

382.25K

Avg. Volume

607.63K

Financials (TTM)

Gross Profit

$6.70B

Operating Income

$2.62B

EBITDA

$5.38B

Operating Cash Flow

$1.80B

Capital Expenditure

-$408.39M

Free Cash Flow

$1.39B

Cash & ST Invst.

$1.83B

Total Debt

$20.78B

Bausch Health Companies Performance Analysis

Bausch Health Companies annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 10,576,257,7400.0%
20232023-12-31USD 11,819,208,75211.8%
20242024-12-31USD 13,185,880,23711.6%
20252025-12-31USD 14,344,564,4178.8%
Bausch Health Companies sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-64.0%
Q42025-12-31211.3%
Q12026-03-31-12.6%
Q22026-06-3011.9%
Bausch Health Companies annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.81-75.6%
20232023-12-31USD -2.19170.6%
20242024-12-31USD -0.17-92.2%
20252025-12-31USD 0.59N/A
Bausch Health Companies sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3014.6%
Q42025-12-31-166.0%
Q12026-03-31-1119.4%
Q22026-06-30117.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$2.78B

+9.8%

Gross Profit

$1.81B

+2.3%

Gross Margin

65.04%

N/A

Market Cap

CA$3.30BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

CA$162.68K

N/A

Employees

20,300

N/A

Net Income

$251.34M

+69.8%

EBITDA

$1.03B

+12.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$1.83B

+5.7%

Total Debt

$20.78B

-4.4%

Accounts Receivable

$2.26B

+2.4%

Inventory

$1.60B

-3.2%

Long Term Debt

$19.90B

-4.6%

Short Term Debt

$881.00M

+0.2%

Return on Assets

-4.43%

N/A

Return on Invested Capital

13.63%

N/A

Free Cash Flow

$593.00M

+213.8%

Operating Cash Flow

$670.00M

+131.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CURA.TOCuraleaf Holdings, Inc.
CA$12.89-4.52%
CRON.TOCronos Group Inc.
CA$4.31-2.27%
TLRY.TOTilray Brands, Inc.
CA$6.37-2.75%
CPH.TOCipher Pharmaceuticals Inc.
CA$14.12+0.93%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$15.16+0.09%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.76+0.01%
ONDSOndas
$9.10+0.02%
SPCXSpace Exploration Technologies
$139.10-0.02%

Questions About BHC

What is the current price of Bausch Health Companies?

Bausch Health Companies is trading at CA$8.95 per share.

What is the 52-week range for Bausch Health Companies?

Over the past 52 weeks, Bausch Health Companies has traded between CA$6.10 and CA$11.97.

How much debt does Bausch Health Companies have?

As of the most recent reporting period, Bausch Health Companies reported total debt of $29.48B.

How much cash does Bausch Health Companies have on hand?

Bausch Health Companies reported $2.61B in cash and cash equivalents in its most recent financial results.

What is Bausch Health Companies’s dividend yield?

Bausch Health Companies does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services